ReviewPathogens (Basel, Switzerland)2022
Review in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Dematiaceous Fungal Infections in Hematopoietic Stem Cell Transplantation and Predisposing Hematological Conditions: A Systematic Review.Journal of fungi (Basel, Switzerland) · 2026Review
- Non-Candida fungal cholecystitis - an uncommon occurrence even in the right host.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Article
- DisseminatedBMJ case reports · 2026Article
- Differences in Clinical Outcomes Among Patients With Mold Fungemia.Open forum infectious diseases · 2026Article
- Masquerading Yeast: A Case Report ofOpen forum infectious diseases · 2025Article
- Computational design of an mRNA vaccine targeting antifungal-resistant Lomentospora prolificans.Scientific reports · 2025Article
- Successful management ofMedical mycology case reports · 2025Article
- Clinical Significance and Therapeutic Challenges ofJournal of fungi (Basel, Switzerland) · 2025Article
- Clinical aspects and recent advances in fungal diseases impacting human health.The Journal of antimicrobial chemotherapy · 2025Review
- Successful Treatment of Lomentospora Prolificans Infection Following Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Literature Review.Infection and drug resistance · 2025Article
- Emerging Fungal Infections of the Central Nervous System in the Past Decade: A Literature Review.Infectious disease reports · 2024Review
- Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections.Clinical microbiology reviews · 2024Review
- Antifungal pipeline: Is there light at the end of the tunnel?World journal of clinical cases · 2024Article
- DisseminatedIDCases · 2024Article
- Article
- Microwave-Assisted Synthesis of Aminophosphonic Derivatives and Their Antifungal Evaluation againstMolecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
objectiveTo systematically address all relevant evidence regarding
methodsWe searched Medline via PubMed and Scopus databases through July 2022. We performed a qualitative synthesis of published articles reporting disseminated infections from
resultsA total of 87 studies describing 142 cases were included in our systematic review. The pathogen was most frequently reported in disseminated infections in Spain (n = 47), Australia (n = 33), the USA (n = 21), and Germany (n = 10). Among 142 reported cases, 48.5% were males. Underlying conditions identified for the majority of patients included malignancy (72.5%), hemopoietic stem cell transplantation (23.2%), solid organ transplantation (16%), and AIDS (2%). Lungs, central nervous system, skin, eyes, heart and bones/joints were the most commonly affected organs. Neutropenia was recorded in 52% of patients. The mortality rate was as high as 87.3%.
conclusionsTo the best of our knowledge, this is the first systematic review conducted on disseminated infections due to this rare microorganism. Physicians should be aware that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.